Trials / NCT03566147
Treatment of RP and LCA by Primary RPE Transplantation
Status unknown Early Phase 1 Gene therapy
- Sponsor
- Eyecure Therapeutics Inc.
- Treatment
- Human primary Retinal Pigment Epithelial (HuRPE) cells
- Gene
- Not stated
- Conditions
- Leber Congenital Amaurosis, Retinitis Pigmentosa
- Ages
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Started
- 2018-08-01
- Main results expected
- 2019-12-31
- Results posted
- Not yet
- Record last updated
- 2018-08-09
What the study is testing
Early Phase I Study of the Safety and Preliminary Efficacy of Human primary Retinal Pigment Epithelial (HuRPE) Cells Subretinal Transplantation in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Patients
Where it runs
China (1)
- Beijing Tongren Hospital, Beijing (recruiting now)